Last reviewed · How we verify
estriol cream
estriol cream is a Estrogen receptor agonist Small molecule drug developed by Hatice Tukenmez Kurnaz. It is currently FDA-approved for Vaginal atrophy and urogenital symptoms associated with menopause, Atrophic vaginitis.
Estriol cream delivers the estrogen hormone estriol topically to provide localized or systemic estrogen replacement therapy.
Estriol cream is used to study various conditions, including vaginal health, genitourinary syndrome of menopause, and uterine health, in clinical trials. The exact mechanism of estriol cream is unknown, as per ChEMBL database.
At a glance
| Generic name | estriol cream |
|---|---|
| Sponsor | Hatice Tukenmez Kurnaz |
| Drug class | Estrogen receptor agonist |
| Target | Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) |
| Modality | Small molecule |
| Therapeutic area | Gynecology / Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Estriol is a weak estrogen that binds to estrogen receptors in vaginal and urogenital tissues, promoting epithelial proliferation, improving vaginal lubrication, and restoring tissue elasticity. The cream formulation allows for direct application to affected tissues, reducing systemic exposure compared to oral hormone replacement therapy while addressing menopausal symptoms such as vaginal atrophy and urogenital dysfunction.
Approved indications
- Vaginal atrophy and urogenital symptoms associated with menopause
- Atrophic vaginitis
Common side effects
- Vaginal irritation or burning
- Headache
- Breast tenderness
- Vaginal bleeding or spotting
Key clinical trials
- Er:YAG Laser Combined With Vaginal Estriol for Genitourinary Syndrome of Menopause (NA)
- Effect of Local Estriol Treatment Before Vaginal Repair Surgery (PHASE3)
- Use of Estriol at Distal Third of Vagina Improving Coital Pain in Post-menopause Women (PHASE1)
- Changes in Neighbouring Microbiota in Genitourinary Syndrome (PHASE4)
- Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit (PHASE4)
- Photobiomodulation Effect on Vulvovaginal Atrophy in Postmenopausal Women. (PHASE2)
- Pharmacological Preparation of the Cervix for Hysteroscopy (NA)
- Vaginal Estriol in Multiple Sclerosis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- estriol cream CI brief — competitive landscape report
- estriol cream updates RSS · CI watch RSS
- Hatice Tukenmez Kurnaz portfolio CI
Frequently asked questions about estriol cream
What is estriol cream?
How does estriol cream work?
What is estriol cream used for?
Who makes estriol cream?
What drug class is estriol cream in?
What development phase is estriol cream in?
What are the side effects of estriol cream?
What does estriol cream target?
Related
- Drug class: All Estrogen receptor agonist drugs
- Target: All drugs targeting Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
- Manufacturer: Hatice Tukenmez Kurnaz — full pipeline
- Therapeutic area: All drugs in Gynecology / Endocrinology
- Indication: Drugs for Vaginal atrophy and urogenital symptoms associated with menopause
- Indication: Drugs for Atrophic vaginitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing